-
Research
- Experts
In The News
View AllMSN features Dr. Brian Dixon
Brian Dixon, PhD, MPA, was featured on MSN about a...
Influence
View AllIs the Multitarget Stool DNA Test Just a Better “FIT” for Colorectal Cancer Screening?
Published in the journal JAMA Internal Medicine. Here is a...
- Opportunities
Featured Fellowship
View all- About
Regenstrief envisions a world where better information empowers people to end disease and realize true health.
- The Latest
- Experts
Drug Safety
The right medicine for the best care
Regenstrief’s Drug Safety Informatics (DSI) Lab exists to further our understanding of how medications interact with each other, and what happens when a drug exits the controlled environment of clinical trials and enters the market and is impacted by variables of adherence. Researchers in the DSI Lab leverage a robust repository of patient data, sophisticated clinical information systems, and expertise in pharmacoepidemiology, data mining, and natural language processing to improve the identification and communication of drug safety issues.
Regenstrief’s unique end-to-end role in the health care environment allows DSI researchers to not only conduct pharmacovigilance studies using observational data, but to influence the collection of key information at the point-of-care to improve these studies.
Ongoing research includes analysis of patterns in adverse event labeling, delivery of customized drug safety information based on patient characteristics, identifying novel drug interactions through literature mining and clinical validation, testing of novel statistical methodologies for pharmacovigilance, design of context-aware drug interaction alerting systems, and applications of information visualization in drug safety.
Projects
Related News & Stories
Dr. Weiner: Prescribing opioids for the treatment of chronic cough
The right medicine for the best care Regenstrief’s Drug Safety Informatics (DSI) Lab exists to further our understanding of how medications interact with each other, and…
Dr. Kurt Kroenke: Restraint in prescribing benzodiazepines
Dr. Kurt Kroenke cautions that benzodiazepines should not be used as first-line treatment for anxiety.
Dr. Noll Campbell on why pharmacists are well-suited for deprescribing
Noll Campbell, PharmD, speaks about the findings from his study about the deprescribing of anticholinergic medications.
Pharmacist-based deprescribing successfully reduced older adults’ exposure to anticholinergic drugs
Anticholinergics, a class of drugs frequently prescribed for depression, urinary incontinence and many other conditions common in older adults, affect the brain by blocking acetylcholine, a...
Challenges of deprescribing and minimizing use of anticholinergic medications
Commonly prescribed drug class strongly associated with cognitive impairment in older adults Medications with anticholinergic properties have been consistently associated with a wide range of adverse...
Regenstrief research scientist briefs FDA on use and misuse of benzodiazepines
The widespread nonmedical use — specifically abuse, misuse and addiction — of benzodiazepines , a class of psychoactive drugs which includes some of the most commonly...
Evaluating the link between medications and dementia: Regenstrief researcher provides consultation
Regenstrief Institute research scientist Noll Campbell, PharmD, M.S., recently contributed to a study that made national headlines and provided more evidence that anticholinergic medications are linked...
Novel app designed to help patients avoid drugs linked to dementia
Researcher awarded $3.5 million to study effectiveness of technology intervention aimed at older adults Indiana University School of Medicine, Regenstrief Institute and Purdue University, led by...
Can Deprescribing Drugs Linked to Cognitive Impairment Actually Reduce Risk of Dementia?
JAMA Internal Medicine commentary highlights opportunity to discover modifiable risk factors for dementia In a commentary published in JAMA Internal Medicine, three Regenstrief Institute research scientists...
Regenstrief scientist explains how class of drugs may be related to dementia
Regenstrief research scientist Noll Campbell, PharmD, M.S., spoke about a common class of drugs and how it affects the brain on an Indianapolis radio show. Dr....
First study to see if de-prescribing commonly used drug class prevents or delays dementia
Regenstrief researcher receives $3.3 million NIA award for cause and effect study Regenstrief Institute research scientist Noll Campbell, PharmD, MS has received a five-year $3.3 million...
Prevention and Treatment of ICU Acquired Delirium Requires Personalized Approach
A population heath study from the Regenstrief Institute and Indiana University Center for Aging Research has determined that haloperidol, the drug most commonly used to treat...
Regenstrief Investigator Discusses “OneSheet Prototype” as Conference Keynote Speaker
Chris Harle, PhD, from Regenstrief Institute and Indiana University Richard M. Fairbanks School of Public Health, gave a keynote speech at the Patient-Centered Clinical Decision Support...
Controlling blood pressure even when older can prevent dementia in African Americans
INDIANAPOLIS – Controlling blood pressure with any of the commonly prescribed antihypertensive medications can prevent dementia in older African-Americans with hypertension according to a new study...
Rapidly meeting the mental health needs of older adults
INDIANAPOLIS — Nearly 20 percent of older Americans experience depression and the highest rate of suicide is among older adult Caucasian males. Despite the anticipated growth...
Commonly used drugs lead to more doctor’s office, hospital and emergency department visits
Anticholinergic medications, a class of drugs commonly used by older adults, are linked to an increased rate of emergency department and hospital utilization in the United...